Multiple Myeloma MM 195 – FASTER

Frontline T-cell engager vs Autologous Stem cell Transplant and measurable residual disease (MRD)-guided sequential intensification thERapy in multiple myeloma (FASTER)

Description

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).

Sponsor: SCRI Development Innovations, LLC

Interested in this trial? Email [email protected].

Back To Clinical Trials NCI Database Entry